Dermata Advances Second Tome Skincare Product Toward Expected 2027 Launch with Initiation of Acne Clinical Trial
Key Highlights
- ➤Dermata enrolls first participant in Tome Clearing Treatment acne clinical trial
- ➤Tome Clearing Treatment expected to launch in H1 2027
- ➤Trial expected to enroll approximately 24 acne participants for 12 weeks
- ➤Once-weekly treatment combines salicylic acid with Dermata’s Bioneedle powder
- ➤Dermata’s first commercial product, Tome Foundational Treatment, is now available
Expert Statements
Gerry Proehl, Chairman, President and Chief Executive Officer of Dermata Therapeutics
“With our Tome Foundational Treatment for skin renewal now commercially available, we are focused on driving growth of our Tome skincare product portfolio and building a scalable business around our differentiated Bioneedle technology.”
Gerry Proehl, Chairman, President and Chief Executive Officer of Dermata Therapeutics
“The initiation of this clinical trial represents an important step toward introducing our second Tome product, which we expect to launch in the first half of 2027. With most topical OTC acne treatments needing to be applied once or twice a day, we believe there is a meaningful commercial opportunity for an effective, convenient, once-weekly treatment that simplifies traditional acne care.”
Gerry Proehl, Chairman, President and Chief Executive Officer of Dermata Therapeutics
“Importantly, we believe our experience in dermatologic clinical development provides a competitive advantage as we build the Tome skincare brand. Our strategy is to combine differentiated products with clinical evidence that can help build consumer confidence, support our marketing efforts, and drive long-term growth.”
SAN DIEGO, CA / ACCESS Newswire / October 29, 2026 / Dermata Therapeutics, Inc. (Nasdaq:DRMA) ("Dermata" or the "Company"), a science-driven leader in dermatologic solutions, today announced enrollment of the first participant in a clinical trial evaluating Tome Clearing Treatment, the Company's once-weekly acne treatment, in participants with acne. The Company expects to launch this second commercial product in H1 2027.
The initiation of this clinical trial marks another milestone in Dermata's strategy by adding a second product to its Tome skincare portfolio, targeting significant opportunities in the consumer skincare market. Acne affects approximately 50 million Americans annually, representing a substantial market for accessible, effective, and convenient treatment options. Tome Clearing Treatment kits salicylic acid, an FDA-recognized over-the-counter ("OTC") acne active ingredient, with Dermata's Bioneedle(™) powder in a differentiated once-weekly treatment regimen. The study is designed to evaluate improvements in acne lesions and post-inflammatory hyperpigmentation, with the goal of generating clinical evidence to support the product's planned commercialization.
Get started
Create a free account to read the full story.